Twist Bioscience vs Veracyte
Veracyte is the larger business, with $517m of revenue in fiscal 2025 against $377m for Twist Bioscience (1.4 times as much). Twist Bioscience grew faster (20.3% against 16.0%). Veracyte kept more of each dollar of sales as profit: a net margin of 12.8% against -20.6%. Twist Bioscience carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Twist BioscienceTWST, 2025 | VeracyteVCYT, 2025 |
|---|---|---|
| Revenue | $377m | $517m |
| Revenue growth | 20.3% | 16.0% |
| Net income | −$77.7m | $66.4m |
| Operating margin | -36.2% | 11.2% |
| Net margin | -20.6% | 12.8% |
| Return on equity | -16.4% | 5.3% |
| Free cash flow | −$75.6m | $127m |
| Cash | $183m | $363m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 979 | 755 |
| Market value | $8.74bn | $4.04bn |
| Price vs our value range | — | Above our value range |
| Moat score | 11 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 0 buys, 180 sales | 0 buys, 61 sales |